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Abstract 
Background: Patients with inflammatory bowel disease (IBD) and intestinal Behçet’s disease (BD) are vulnerable to 
micronutrient deficiencies due to diarrhea-related gastrointestinal loss and poor dietary intake caused by disease-
related anorexia. However, few studies have investigated the incidence and risk factors for micronutrient deficiency.
Methods: We retrospectively analyzed 205 patients with IBD who underwent micronutrient examination, includ-
ing folate, vitamin B12, 25-OH-vitamin D, and/or ferritin level quantification, with follow-up blood tests conducted 
6 months later.
Results: Eighty patients (39.0%), who were deficient in any of the four micronutrients, were classified as the defi-
ciency group, and the remaining 125 (61.0%) were classified as the non-deficient group. Compared to those in the 
non-deficiency group, patients in the deficiency group were much younger, had more Crohn’s disease (CD) patients, 
more patients with a history of bowel operation, and significantly less 5-amino salicylic acid usage. Multivariate 
analysis revealed that CD and bowel operation were significant independent factors associated with micronutrient 
deficiency.
Conclusions: The incidence of micronutrient deficiency was high (39.0%). Factors including CD, bowel operation, 
and younger ages were found to be associated with higher risks of deficiency. Therefore, patients with IBD, especially 
young patients with CD who have undergone bowel resection surgery, need more attention paid to micronutrition.
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Background
Inflammatory bowel disease (IBD), including Crohn’s dis-
ease (CD) and ulcerative colitis (UC), is a chronic disease 
of the gastrointestinal (GI) tract associated with unclear 
etiology, leading to rectal bleeding, abdominal pain, and 
weight loss and repeated cycles of relapse and remission 
[1, 2]. CD is an IBD that can affect entire GI tract from 
mouth to anus and it affects mainly terminal ileum and 
colon. It often includes both intestinal and extra-intes-
tinal symptoms [2, 3]. On the other hand, UC is mostly 
restricted to the colon and it usually involves continu-
ous lesion in the intestinal mucosa [2]. Most patients 
with IBD, especially those with CD, suffer from weight 
loss and malnutrition during the course of the disease [4, 
5], which may be related to lack of oral intake, increased 
nutrient requirements, increased GI loss, and intestinal 
resection or bypass surgery [4, 6]. In addition, intestinal 
Behçet’s disease (BD), which is an intestinal invasion of 
BD with chronic relapsing multisystem vasculitis disorder 
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[7], is similar to CD with respect to clinical courses, 
symptoms and treatment modalities [8]. Therefore, there 
is increasing interest in patient management and nutri-
tional status in intestinal BD as well as IBD.
Nutrients can be classified as either macronutrients 
or micronutrients. Macronutrients are energy-providing 
nutrients including carbohydrates, lipids, and proteins. 
Malnutrition can occur in cases of active, severe IBD, 
when macronutrients are not consumed or absorbed in 
sufficient quantities. Micronutrients, including miner-
als, vitamins, and trace elements, are often deficient in 
patients with mild disease activity or remission status [9, 
10].
According to the European Society for Clinical Nutri-
tion and Metabolism guidelines, patients with IBD 
should be regularly checked for micronutrient deficien-
cies and certain deficits should be adequately corrected 
[11]. Several studies have reported vitamin and mineral 
deficiencies in patients with IBD; these studies assessed 
their symptoms and effects on the quality of life and 
observed widely variable clinical significance [12–14]. 
Vitamins are organic compounds and are classified as 
either water-soluble, including thiamine (B1), riboflavin 
(B2), nicotinic acid/niacin (B3), pyridoxine (B6), cobala-
min (B12), biotin, pantothenic acid, folic acid, and vita-
min C (ascorbic acid), or fat-soluble, including vitamins 
A, D, E, and K [9]. Dietary minerals are important inor-
ganic components that work as cofactors and catalysts in 
maintaining cell structure and enzymatic processes, such 
as calcium, phosphate, potassium, magnesium, and iron. 
Trace elements are necessary for the function of enzymes 
in the body, including zinc, copper, and selenium [9, 10].
Clinically relevant micronutrient deficiencies that 
occur over the course of IBD disease progression include 
anemia (caused by iron, folate, and vitamin B12 defi-
ciencies), bone mineral density loss (due to insufficient 
calcium, vitamin D, magnesium, and vitamin K levels), 
impaired thrombosis (caused by folate, vitamin B6, B12 
deficiency) and wound healing deficits (due to defi-
ciencies of vitamin A, C, and zinc), and carcinogenesis 
(related to folate, vitamin D, and calcium deficiency) [9]. 
Among them, anemia is the most common complica-
tion affecting up to 70% of patients with IBD, including 
UC and CD, and intestinal BD [15, 16]. Iron deficiency 
is the most common cause of anemia in 30–90% of 
patients with IBD, but folate and vitamin B12 deficien-
cies are also highly prevalent in these patients, especially 
in those with CD, compared to the general population 
[17–19]. In addition, bone density is an important factor, 
which affects not only the quality of life of IBD patients 
but also the disease course of IBD, as it is highly related 
to treatment modalities such as corticosteroids as well 
as micronutrients [20–22]. However, studies assessing 
micronutrient concentrations in patients with IBD are 
scarce, and there are currently no studies on micronu-
trients in patients with intestinal BD, to our knowledge. 
Therefore, we aimed to investigate the prevalence and 
risk factors of micronutrient deficiency in patients with 
IBD and intestinal BD.
Methods
Patients
We conducted a retrospective study of patients with 
IBD and intestinal BD who underwent laboratory tests 
to quantify micronutrients such as iron, folate, vitamin 
B12, and 25-OH-vitamin D from March 2016 to March 
2017 at the Severance Hospital, Yonsei University Col-
lege of Medicine, Seoul, Korea. Out of 3,695 patients, a 
total of 205 with IBD and intestinal BD who underwent 
micronutrient testing twice were enrolled retrospectively. 
A total of 3,490 patients were excluded from our study 
for the following reasons: (1) patients did not undergo 
micronutrient testing during the study period (n = 3,047); 
(2) patients underwent micronutrient blood testing only 
once (n = 426); (3) data were not available or were lost to 
follow-up (n = 10); and (4) patients diagnosed with other 
diseases such as cancer or non-specific inflammation 
after evaluation (n = 7) (Fig. 1).
We included patients who underwent micronutrient 
testing at least twice, at baseline and at follow-up after 
6  months for one or more of the following four micro-
nutrients: folate (n = 127), vitamin B12 (n = 128), 25-OH-
vitamin D (n = 184), and ferritin (n = 97). In addition, 
we divided patients into two groups: a group consisting 
of those with a micronutrient deficiency (n = 80) and 
another group with those without micronutrient defi-
ciency (n = 125) at baseline. This study was performed in 
accordance with the ethical guidelines of the 1975 Decla-
ration of Helsinki and was approved by the institutional 
review board of Severance Hospital.
Baseline characteristics
Variables of baseline characteristics included demo-
graphic information, routes of laboratory tests (outpa-
tients or inpatients), medications, supplements, past 
bowel surgery, and underlying diseases.
Definitions
We defined deficient levels of folate and vitamin B12 as <
3.38  ng/mL (folate N: 3.38–48.0  ng/mL) and < 211  pg/
mL (vitamin B12 N: 211–911 pg/mL), respectively. Iron 
deficiency was defined as ferritin levels < 10  ng/mL (N: 
10–291  ng/mL). Serum 25-OH-vitamin D testing was 
performed to identify vitamin D deficiency, with vitamin 
D deficiency defined as < 10 ng/mL (50 nmol/L).
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In our study, we defined bowel surgery as cases of sur-
gery due to diseases of IBD and intestinal BD only, and 
excluded all the other causes including diverticulum and 
foreign body.
Statistical analysis
Variables are expressed as either median (interquartile 
range, IQR) or n (%). Baseline characteristics were com-
pared using independent Student’s t-tests (or Mann–
Whitney tests) for continuous variables, and χ2 tests (or 
Fisher’s exact tests) were used for categorical variables, 
as appropriate. Independent predictors of micronutrient 
deficiency were analyzed using logistic regression analy-
sis. Odds ratios (ORs) and the corresponding 95% confi-
dence intervals (CIs) were calculated. Data analysis was 
performed using Statistical Package for the Social Sci-
ences (SPSS) software (version 20.0; SPSS Inc., Armonk, 




Micronutrient deficiency was observed in 80 (39.0%) of 
205 patients who were tested over the year beginning 
March 2016. Baseline characteristics of the micronutri-
ent deficient and non-deficient groups were analyzed and 
are summarized in Table  1. Among the micronutrients 
assessed, 25-OH-vitamin D was quantified in 90.2% of 
patients, and vitamin B12, folate and ferritin testings were 
performed for 47.3–62.4% of patients. The proportions 
of folate (80.0% vs. 50.4%; P < 0.001), vitamin B12 (80.0% 
vs. 51.2%; P < 0.001), and ferritin tests (60.0% vs. 39.2%; 
P = 0.004) were significantly higher in the micronutri-
ent deficiency group while 25-OH-vitamin D test was 
lower than the non-deficiency group (83.8% vs. 94.4%; 
P = 0.013). The number of subjects found with defi-
ciency of each micronutrient was 10 (12.5%) for folate, 20 
(25.0%) for vitamin B12, 21 (26.3%) for 25-OH-vitamin D, 
and 45 (56.3%) for ferritin in the micronutrient deficiency 
group. Patients with CD exhibited a greater prevalence of 
micronutrient deficiency than those with UC or intesti-
nal BD (82.5% vs. 11.3% vs. 6.3%; P = 0.003).
The median age was 34 years [IQR, 19–47], and 57.6% 
of the enrolled patients were male. In addition, most 
patients underwent laboratory testing in an outpatient 
clinic setting compared to an inpatient setting (93.2% vs. 
6.8%; P = 0.150). There were no significant differences 
in most of the types of medications used by patients, 
but there were significantly more users of 5-aminosali-
cylic acid (5-ASA) in the non-deficient group (41.3% vs. 
64.8%; P = 0.001). Micronutrient deficiency was higher in 
patients who underwent previous bowel surgery to treat 
Fig. 1 Patients enrollment
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the disease than in those who had not previously under-
gone disease-related surgery (41.3% vs. 25.6%; P = 0.019) 
(Table 1).
Relative risk of micronutrient deficiency
Based on the univariate analysis, variables that were 
negatively associated with micronutrient deficiency with 
Table 1 Baseline characteristics between micro-nutrient deficiency group and non-deficiency group
Data are expressed as median (interquartile range, IQR) or n (%). *P-value for comparing patients with micronutrient deficiency group and non-deficiency group
IBD, Inflammatory bowel disease; UC, Ulcerative colitis; CD, Crohn’s disease; BD, Behçet’s disease; 5-ASA, 5-aminosalicylic acid; anti-TNF, anti-tumor necrosis factor; 
6-MP, 6-mercaptopurine; SERM, Selective estrogen receptor modulators
a Mongersen, vedolizumab
b Myelodysplastic syndrome, Systemic lupus erythematosus, aortic valve disease, Bronchiolitis obliterans with organizing pneumonia, osteoarthritis, coronary artery 
occlusive disease, cancer
Variables Total (n = 205) Micro-nutrient deficiency 
group (n = 80, 39.0%)
Non-deficiency group 
(n = 125, 61.0%)
P-value
Male sex 118 (57.6) 44 (55.0) 74 (59.2) 0.553
Age 34 (19–47) 27 (19–41) 37 (20–51) 0.003
The path of laboratory test 0.150
 Outpatients clinic 191 (93.2) 72 (90.0) 119 (95.2)
 Hospitalization patients 14 (6.8) 8 (10.0) 6 (4.8)
Number of micronutrient tests
 Folate 127 (62.0) 64 (80.0) 63 (50.4)  < 0.001
 Vitamin B12 128 (62.4) 64 (80.0) 64 (51.2)  < 0.001
 25-OH-vitamin D 184 (90.2) 67 (83.8) 117 (94.4) 0.013
 Ferritin 97 (47.3) 48 (60.0) 49 (39.2) 0.004
Type of IBD 0.003
 UC 49 (23.9) 9 (11.3) 40 (32.0)
 CD 143 (69.8) 66 (82.5) 77 (61.6)
 Intestinal BD 13 (6.3) 5 (6.3) 8 (6.4)
Medications
 5-ASA 114 (55.6) 33 (41.3) 81 (64.8) 0.001
 Steroids 12 (5.9) 3 (3.8) 9 (7.2) 0.305
 Azathioprine 66 (32.2) 32 (40.0) 34 (27.2) 0.056
 Anti-TNF 101 (49.3) 45 (56.3) 56 (44.8) 0.110
 Methotrexate 33 (16.1) 11 (13.8) 22 (17.6) 0.464
 6-MP 2 (1.0) 0 (0) 2 (1.6) 0.256
 Othersa 12 (5.9) 2 (2.5) 10 (8.0) 0.102
Supplementary medications
 Iron supplementation 77 (37.6) 43 (53.8) 34 (27.2)  < 0.001
 Folate supplementation 50 (24.4) 26 (32.5) 24 (19.2) 0.031
 Multivitamin 52 (25.4) 21 (26.3) 31 (24.8) 0.816
 Calcium, Vitamin D supplementation 127 (62.0) 51 (63.7) 76 (60.8) 0.671
 Vitamin B12 supplementation 43 (21.0) 30 (37.5) 13 (10.4)  < 0.001
 Vitamin C supplementation 3 (1.5) 0 (0) 3 (2.4) 0.163
 Zinc supplementation 7 (3.4) 3 (3.8) 4 (3.2) 0.832
 Osteoporosis medication
 SERM 3 (1.5) 1 (1.3) 2 (1.6) 0.839
 Bisphosphonate 14 (6.8) 1 (1.3) 13 (10.4) 0.011
Operation 65 (31.7) 33 (41.3) 32 (25.6) 0.019
Underlying disease
 Hypertension 4 (2.0) 1 (1.3) 3 (2.4) 0.561
 Diabetes 1 (0.5) 0 (0) 1 (0.8) 0.423
 Osteoporosis 38 (18.5) 13 (16.3) 25 (20.0) 0.500
 Othersb 46 (22.4) 19 (23.8) 27 (21.6) 0.719
Page 5 of 9Park et al. BMC Gastroenterol           (2021) 21:32  
statistical significance included age (OR, 0.975; 95% CI 
0.958–0.993; P = 0.006) and 5-ASA usage (OR, 0.381; 
95% CI 0.214–0.679; P = 0.001). In addition, CD (com-
pared to those with UC or intestinal BD) (OR, 3.810; 95% 
CI 1.721–8.430; P = 0.001) and previous disease-related 
surgical operations (OR, 2.041; 95% CI 1.120–3.717; 
P = 0.020) were significantly associated with micronutri-
ent deficiency (Table 2). Based on the multivariate analy-
sis assessing variables including male sex, age, the path of 
laboratory test, types of intestinal disease, medications, 
previous surgical operations, and other underlying dis-
eases, CD (compared with UC or intestinal BD) (adjusted 
OR, 2.492; 95% CI 1.012–6.136; P = 0.047) and previous 
disease-related surgical operations (adjusted OR, 2.714; 
95% CI 1.260–5.844; P = 0.011) were identified to be 
associated with higher risks of micronutrient deficiency. 
Conversely, age (adjusted OR, 0.973; 95% CI 0.949–0.998; 
P = 0.037) was negatively associated with micronutrient 
deficiency (Table 2).
Changes in micronutrient levels
Patients with UC and CD had the highest rates of fer-
ritin deficiency compared to the other micronutrients 
assessed, including vitamin B12, folate, and 25-OH-
vitamin D, while in those with intestinal BD, the defi-
ciency did not vary among the micronutrients assessed. 
However, rates of vitamin B12 deficiency significantly 
differed among those with UC, CD, and intestinal BD 
(0% vs. 13.7% vs. 18.2%, respectively; P = 0.038) (Fig. 2).
We assessed changes from baseline at the first 
6-month follow-up in terms of folate, vitamin B12, 
25-OH-vitamin D, and ferritin levels in this study 
population. Initial laboratory tests in patients with 
UC showed ferritin and 25-OH-vitamin D deficiency, 
which had improved at follow-up testing after supple-
mentation. In patients with CD, ferritin, vitamin B12, 
25-OH-vitamin D, and folic acid deficiency occurred, 
and ferritin deficiency was the highest. Patients with 
intestinal BD had more deficiencies in folic acid and 
vitamin B12 than ferritin and 25-OH-vitamin D. In all 
cases, deficiencies were treated at the time of discovery, 
and after 6 months, all micronutrient deficiencies were 
reduced (Fig. 3).
Table 2 Relative risk of micro-nutrient deficiency
OR, odds ratio; CI, confidence interval; UC, Ulcerative colitis; CD, Crohn’s disease; BD, Behçet’s disease; 5-ASA, 5-aminosalicylic acid; anti-TNF, anti-tumor necrosis factor
a Mongersen, vedolizumab
b MDS, SLE, AR, BOOP, OA, Osteoporosis, CAOD, cancer
Variable Uni-variate analysis Multi-variate analysis
OR (95% CI) P-value Adjusted OR (95% CI) P-value
Male sex 0.842 (0.478–1.485) 0.553 0.718 (0.375–1.376) 0.319
Age 0.975 (0.958–0.993) 0.006 0.973 (0.949–0.998) 0.037
The path of laboratory test
 Outpatients clinic 1.0 (Ref.) 1.0 (Ref.)
 Hospitalization patients 2.204 (0.735–6.608) 0.158 2.459 (0.715–8.461) 0.154
Type of disease
 UC 1.0 (Ref.) 1.0 (Ref.)
 CD 3.810 (1.721–8.430) 0.001 2.492 (1.012–6.136) 0.047
 Intestinal BD 2.778 (0.734–10.513) 0.132 1.356 (0.284–6.479) 0.703
Medications
 5-ASA 0.381 (0.214–0.679) 0.001 0.548 (0.281–1.068) 0.077
 Steroids 0.502 (0.132–1.914) 0.313
 Azathioprine 1.784 (0.983–3.238) 0.057
 Anti-TNF 1.584 (0.900–2.788) 0.111
 Methotrexate 0.746 (0.340–1.637) 0.465
 Othersa 0.295 (0.063–1.383) 0.121
Operation 2.041 (1.120–3.717) 0.020 2.714 (1.260–5.844) 0.011
Underlying disease
 Hypertension 0.515 (0.053–5.037) 0.568
 Osteoporosis 0.776 (0.371–1.624) 0.501 1.500 (0.699–3.217) 0.298
 Othersb 1.131 (0.579–2.206) 0.719 2.459 (0.715–8.461) 0.154
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Discussion
The study found that micronutrient deficiency was high 
(39.0%) in patients with IBD and intestinal BD, and 83% 
of the deficiency group were CD patients. In IBD patients 
with CD or UC, ferritin deficiency was significant, as was 
25-OH-vitamin D deficiency. However, patients with 
intestinal BD had more folic acid and vitamin B12 defi-
ciencies than those with IBD, who had more ferritin and 
25-OH-vitamin D deficiencies. In addition, young age, 
CD, and intestinal surgery were significantly associated 
with micronutrient deficiency.
Hwang et  al. reviewed studies on micronutrient defi-
ciency in patients with IBD and showed prevalence of 
micronutrients deficiencies. Among IBD patients, water-
soluble vitamins deficiencies have been reported up to 
11–78% [19, 23–25]; fat-soluble vitamins deficiencies to 
22–90% [22, 23, 25–28]; and macro mineral deficiencies 
to 36–90% [15, 23, 24, 29–31]. In most studies, patients 
with CD showed a higher correlation with vitamin or 
mineral deficiencies than those with UC. Our study also 
showed a high prevalence (46.2%, 66 of 143 patients) of 
micronutrient deficiency in patients with CD. Most vita-
mins and minerals are absorbed in the proximal small 
intestine, and vitamin B12 is absorbed in the terminal 
ileum [9]. The distal ileum is also where bile acid absorp-
tion occurs, which is important for the absorption of fat 
and fat-soluble vitamins [9]. Therefore, micronutrient 
deficiency should be carefully observed in patients with 
CD, which is relatively invasive in the small intestine and 
frequently affects the terminal ileum. In addition, caution 
should also be exercised in cases of intestinal BD because 
it often manifests as an oval shape and causes deep ulcers 
in the ileocecal area [7]. Therefore, patients with intesti-
nal BD also showed micronutrient deficiencies (38.46%, 
5 of 13), especially vitamin B12 deficiency; there was a 
significant difference among patients with UC, CD, and 
intestinal BD, with the highest prevalence in patients 
with intestinal BD (UC, 0% vs. CD, 13.7% vs. intestinal 
Fig. 2 Frequency of micronutrient deficiency (folate, vitamin B12, 25-OH-vitamin D, and ferritin) for each disease, including ulcerative colitis (UC), 
Crohn’s disease (CD), and intestinal Behçet’s disease (BD)
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BD, 18.2%; P = 0.038) (Fig. 2b). The mostly likely explana-
tion could be due to the location of the intestine affected 
by the disease, as intestinal BD may be associated with 
high cobalamin (vitamin B12) deficiency rates. There-
fore, 156 patients with CD and intestinal BD with simi-
lar invasion sites were analyzed separately, but there was 
no significant difference in the deficiency of micronutri-
ents between CD and BD patients. However, our results 
showed that micronutrient deficiency was as high in 
patients with intestinal BD as well as in patients with CD. 
Further research is needed in a larger study group.
In patients with IBD, surgery is a significantly impor-
tant factor affecting the likelihood of micronutrient defi-
ciency. There have been reports of significantly lower 
vitamin D levels when CD affects the small intestine or 
when the small intestine is excised [32]. Active Crohn’s 
ileitis and small bowel resection are reported to be risk 
factors for folic acid deficiency, as they can lead to mal-
absorption [19, 25]. In addition, Battat et al. reported that 
ileal resection greater than 30 cm was an associated risk 
factor for cobalamin deficiency in patients with CD [33]. 
When further analyzing the risk factors for cobalamin 
deficiency in our study population, disease-related surgi-
cal operation was found to be a significant associated risk 
factor (OR, 5.513; CI 1.829–16.613; P = 0.002; data not 
shown).
Our study is the first report on micronutrient defi-
ciency in patients with intestinal BD and IBD. However, 
the study has several limitations. First, it is a retrospec-
tive cross-sectional study with selection bias. Because 
we examined patients who had been tested for a period 
of 1  year, we could not observe the cumulative effects 
of time to compare what the deficiencies had been 
before the start of the study and whether the deficiency 
occurred again after it ended, even though the deficien-
cies had been treated. This also showed a limit to the 
outcome of the assessment of patients with vitamin D 
deficiency. Even though our study used a lower vitamin 
D deficiency criterion (< 10  ng/mL) than other studies, 
many patients were already taking supplements (62.0%), 
which made it difficult to make a clear comparison. In 
addition, it may include cases in which several micro-
nutrients are deficient in one patient with high risk of 
micronutrient deficiency. Furthermore, deficiency of cer-
tain micronutrients such as vitamin B12 can be affected 
depending on the location of the disease. For example, 
CD and intestinal BD patients are at high risk of vita-
min B12 deficiency, while UC patients are relatively less 
likely to be affected. Therefore, there is a limitation with 
the possibility of selection bias. However, it is meaningful 
that it can analyze the risk of overall micronutrients defi-
ciency. Second, we could not examine the relationship 
Fig. 3 Changes in micronutrient deficiencies (folate, vitamin B12, 25-OH-vitamin D, and ferritin) between the initial and follow-up blood tests after 
six months in patients with ulcerative colitis (UC), Crohn’s disease (CD), and intestinal Behçet’s disease (BD)
Page 8 of 9Park et al. BMC Gastroenterol           (2021) 21:32 
between disease activities. In particular, data on ESR 
(erythrocyte sedimentation rate) and CRP (C-reactive 
protein) levels, medical records of disease activity (CDAI 
[Crohn’s disease activity index], Mayo score, DAIBD 
[Disease Activity Index for Intestinal Behcet’s Disease]), 
and disease extent (Montreal classification) were insuf-
ficient for analysis. Most were outpatient clinic patients 
(93.2%), so we could not obtain accurate disease informa-
tion based solely on the medical records. For example, 
55.6% of the included patients were being treated with 
Pentasa (5-ASA) and 5.9% of patients were treated with 
steroid medications, suggesting most patients were not in 
the acute phase of disease progression. Thus, it may have 
been difficult to clearly compare differences in micro-
nutrient deficiencies among those treated with various 
medications. Nevertheless, it was found that micronu-
trient deficiency was high in the outpatient population 
where the disease activity was not severe.
Conclusions
In conclusion, in patients with IBD and intestinal BD, the 
incidence of micronutrient deficiency was high (39.0%). 
In addition, CD, a history of intestinal surgery, and young 
age were factors significantly associated with deficiency. 
Therefore, those with IBD, especially young patients 
with CD who have undergone bowel resection, should 
be observed more carefully to assess the need for supple-
mentation to treat micronutrient deficiencies.
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